Overview
Multicentric retroprospective observational study to collect outcome in premenopausal breast cancer patients who undergone the 21-multigene assay Oncotype DX from 1st January 2013 to 31st December 2022 and adjuvant treatment.
Description
Premenopausal patients who undergone the 21-multigene assay Oncotype DX from 1st January 2013 to 31st December 2022 with any Recurrence Score (RS) and pathological nodal status pN0/pN1 will be included in the study. The study will collect clinical-pathological, genomic characteristics, adjuvant treatments (chemotherapy, endocrine therapy with/without OFS), and survival outcome (iDFS).
Eligibility
Inclusion Criteria:
- Female, premenopausal and ≥18 years age patients.
- Agree to participate in study and signing informed consent or declaration in lieu of informed consent form, if applicable
- Histological diagnosis of early breast cancer hormone positive (ER and/or PgR), HER2-negative.
- Pathological nodal stage of pN0 or pN1 (1-3 nodes) and pathological tumor stage of pT1 to pT3.
- Surgery for primary breast cancer and axillary staging by sentinel node biopsy or axillary lymph node dissection (ALND).
- Availability of 21-multigene assay Oncotype DX recurrence score results performed according to physician choice from 1st January 2013 to 31st December 2022
- Availability of clinical and pathological information.
- Availability of information about adjuvant treatment received.
- Availability of patient' outcome information (relapse, site of relapse, survival).
Exclusion Criteria:
- Evidence of distant metastases
- Inflammatory breast cancer
- Neoadjuvant treatment
- No surgery for primary breast cancer and axillary staging
- Patients not tested with 21-multigene assay Oncotype DX
